Court restricts telemedicine access to abortion pill mifepristone nationwide

Patients seeking medication abortion may now have to travel to a clinic or pharmacy in person for mifepristone, after a federal appeals court ordered the Food and Drug Administration to restore the drug’s in-person dispensing requirements while litigation continues. The ruling from the U.S. Court of Appeals for the 5th Circuit, issued on May 1 in a Louisiana-led case, immediately halted the 2023 FDA changes that had allowed telehealth prescribing and mail or pharmacy access nationwide.

That shift matters most in places where abortion care is already hard to reach. Patients in states with bans, severe restrictions or long travel distances have relied on telemedicine to avoid delays, extra costs and repeated time off work. Danco Laboratories, which makes mifepristone, has already asked the Supreme Court to pause the ruling.

The case lands in a market that has become dominated by pills. Medication abortions accounted for 63% of all U.S. abortions in 2023, up from 53% in 2020, and more than one million abortions took place in the formal health-care system that year. That means the court order could affect a large share of patients, especially those who had depended on mail delivery, pharmacy pickup or remote prescribing.

Mifepristone itself has been at the center of abortion care for more than two decades. The FDA approved it in 2000 for early pregnancy termination, and the agency later approved a generic version in April 2019. In 2024, the Supreme Court unanimously rejected a challenge to the drug on standing grounds, but litigation over access has continued after Dobbs and now has returned to the appeals courts.

The ruling does not eliminate medication abortion. Misoprostol alone remains a medically accepted option, and major medical guidance has endorsed it as safe and effective. The World Health Organization and other professional groups include misoprostol-only regimens in abortion care recommendations, and a JAMA Network Open study of 637 callers to safe-abortion hotlines and accompaniment groups found that 98.1% had a complete abortion without procedural intervention.

Abortion providers are already preparing to adjust. Planned Parenthood affiliates said they would move to misoprostol-only protocols where needed, and Planned Parenthood of Northern New England said that approach has been used successfully for years where mifepristone is restricted. The National Abortion Federation called the decision a dangerous rollback that adds medically unnecessary barriers, while the American College of Obstetricians and Gynecologists has repeatedly said mifepristone is safe, effective and integral to patient care.

For now, the ruling narrows one of the fastest and most common paths to abortion care in the United States, even as another pill regimen remains available and backed by strong clinical evidence.